Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease

Reuben Matalon, Sankar Surendran, Peter L. Rady, Michael J. Quast, Gerald Campbell, Kimberlee M. Matalon, Stephen K. Tyring, Jingna Wei, Carmen S. Peden, Ed L. Ezell, Nicholas Muzyczka, Ronald J. Mandel

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Canavan disease (CD) is an autosomal recessive leukodystrophy caused by deficiency of aspartoacylase (ASPA). Deficiency of ASPA leads to elevation of N-acetyl-L-aspartic acid (NAA) in the brain and urine. To explore the feasibility of gene transfer to replace ASPA in CD, we generated a knockout mouse and constructed an AAV vector that encodes human ASPA cDNA, (hASPA) followed by green fluorescent protein (GFP) after an intraribosomal entry site. We injected CD mice with rAAV-hASPA-GFP in the striatum and thalamus or injected rAAV-GFP identically into control animals. Three to five months after the injection, we determined the presence of ASPA in the CD mouse brain by ASPA activity assay, GFP expression, and Western blot analysis. While rAAV-GFP-injected animals displayed undetectable levels of ASPA, all detection methods revealed significant ASPA levels in rAAV-hASPA-GFP-injected CD mice. We evaluated the functional effects of rAAV-hASPA-GFP-mediated ASPA expression by standard histological methods, magnetic resonance spectroscopy (MRS) for in vivo NAA levels, and magnetic resonance imaging of CD mice. rAAV-hASPA-injected animals displayed a remarkable lack of spongiform degeneration in the thalamus. However, pathology in sites unrelated to the injected areas showed no improvement in histopathology. The improvement in thalamic neuropathology was also detectable via in vivo MRI. MRS revealed that in vivo NAA levels were also reduced. These data indicate that rAAV-mediated ASPA delivery may be an interesting avenue for the treatment of CD.

Original languageEnglish (US)
Pages (from-to)580-587
Number of pages8
JournalMolecular Therapy
Volume7
Issue number5 I
DOIs
StatePublished - May 1 2003

Fingerprint

Canavan Disease
Dependovirus
Knockout Mice
Green Fluorescent Proteins
Brain
Genes
Complementary DNA
Aspartic Acid
Thalamus
Magnetic Resonance Spectroscopy
aspartoacylase
Western Blotting
Magnetic Resonance Imaging

Keywords

  • AAV-GFP
  • Aspartoacylase
  • Canavan
  • Canavan mice
  • Gene transfer
  • rAAV-hASPA

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. / Matalon, Reuben; Surendran, Sankar; Rady, Peter L.; Quast, Michael J.; Campbell, Gerald; Matalon, Kimberlee M.; Tyring, Stephen K.; Wei, Jingna; Peden, Carmen S.; Ezell, Ed L.; Muzyczka, Nicholas; Mandel, Ronald J.

In: Molecular Therapy, Vol. 7, No. 5 I, 01.05.2003, p. 580-587.

Research output: Contribution to journalArticle

Matalon, R, Surendran, S, Rady, PL, Quast, MJ, Campbell, G, Matalon, KM, Tyring, SK, Wei, J, Peden, CS, Ezell, EL, Muzyczka, N & Mandel, RJ 2003, 'Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease', Molecular Therapy, vol. 7, no. 5 I, pp. 580-587. https://doi.org/10.1016/S1525-0016(03)00066-2
Matalon, Reuben ; Surendran, Sankar ; Rady, Peter L. ; Quast, Michael J. ; Campbell, Gerald ; Matalon, Kimberlee M. ; Tyring, Stephen K. ; Wei, Jingna ; Peden, Carmen S. ; Ezell, Ed L. ; Muzyczka, Nicholas ; Mandel, Ronald J. / Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. In: Molecular Therapy. 2003 ; Vol. 7, No. 5 I. pp. 580-587.
@article{b19d947625fc482ba1ebfa2e899c9f1d,
title = "Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease",
abstract = "Canavan disease (CD) is an autosomal recessive leukodystrophy caused by deficiency of aspartoacylase (ASPA). Deficiency of ASPA leads to elevation of N-acetyl-L-aspartic acid (NAA) in the brain and urine. To explore the feasibility of gene transfer to replace ASPA in CD, we generated a knockout mouse and constructed an AAV vector that encodes human ASPA cDNA, (hASPA) followed by green fluorescent protein (GFP) after an intraribosomal entry site. We injected CD mice with rAAV-hASPA-GFP in the striatum and thalamus or injected rAAV-GFP identically into control animals. Three to five months after the injection, we determined the presence of ASPA in the CD mouse brain by ASPA activity assay, GFP expression, and Western blot analysis. While rAAV-GFP-injected animals displayed undetectable levels of ASPA, all detection methods revealed significant ASPA levels in rAAV-hASPA-GFP-injected CD mice. We evaluated the functional effects of rAAV-hASPA-GFP-mediated ASPA expression by standard histological methods, magnetic resonance spectroscopy (MRS) for in vivo NAA levels, and magnetic resonance imaging of CD mice. rAAV-hASPA-injected animals displayed a remarkable lack of spongiform degeneration in the thalamus. However, pathology in sites unrelated to the injected areas showed no improvement in histopathology. The improvement in thalamic neuropathology was also detectable via in vivo MRI. MRS revealed that in vivo NAA levels were also reduced. These data indicate that rAAV-mediated ASPA delivery may be an interesting avenue for the treatment of CD.",
keywords = "AAV-GFP, Aspartoacylase, Canavan, Canavan mice, Gene transfer, rAAV-hASPA",
author = "Reuben Matalon and Sankar Surendran and Rady, {Peter L.} and Quast, {Michael J.} and Gerald Campbell and Matalon, {Kimberlee M.} and Tyring, {Stephen K.} and Jingna Wei and Peden, {Carmen S.} and Ezell, {Ed L.} and Nicholas Muzyczka and Mandel, {Ronald J.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1016/S1525-0016(03)00066-2",
language = "English (US)",
volume = "7",
pages = "580--587",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5 I",

}

TY - JOUR

T1 - Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease

AU - Matalon, Reuben

AU - Surendran, Sankar

AU - Rady, Peter L.

AU - Quast, Michael J.

AU - Campbell, Gerald

AU - Matalon, Kimberlee M.

AU - Tyring, Stephen K.

AU - Wei, Jingna

AU - Peden, Carmen S.

AU - Ezell, Ed L.

AU - Muzyczka, Nicholas

AU - Mandel, Ronald J.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Canavan disease (CD) is an autosomal recessive leukodystrophy caused by deficiency of aspartoacylase (ASPA). Deficiency of ASPA leads to elevation of N-acetyl-L-aspartic acid (NAA) in the brain and urine. To explore the feasibility of gene transfer to replace ASPA in CD, we generated a knockout mouse and constructed an AAV vector that encodes human ASPA cDNA, (hASPA) followed by green fluorescent protein (GFP) after an intraribosomal entry site. We injected CD mice with rAAV-hASPA-GFP in the striatum and thalamus or injected rAAV-GFP identically into control animals. Three to five months after the injection, we determined the presence of ASPA in the CD mouse brain by ASPA activity assay, GFP expression, and Western blot analysis. While rAAV-GFP-injected animals displayed undetectable levels of ASPA, all detection methods revealed significant ASPA levels in rAAV-hASPA-GFP-injected CD mice. We evaluated the functional effects of rAAV-hASPA-GFP-mediated ASPA expression by standard histological methods, magnetic resonance spectroscopy (MRS) for in vivo NAA levels, and magnetic resonance imaging of CD mice. rAAV-hASPA-injected animals displayed a remarkable lack of spongiform degeneration in the thalamus. However, pathology in sites unrelated to the injected areas showed no improvement in histopathology. The improvement in thalamic neuropathology was also detectable via in vivo MRI. MRS revealed that in vivo NAA levels were also reduced. These data indicate that rAAV-mediated ASPA delivery may be an interesting avenue for the treatment of CD.

AB - Canavan disease (CD) is an autosomal recessive leukodystrophy caused by deficiency of aspartoacylase (ASPA). Deficiency of ASPA leads to elevation of N-acetyl-L-aspartic acid (NAA) in the brain and urine. To explore the feasibility of gene transfer to replace ASPA in CD, we generated a knockout mouse and constructed an AAV vector that encodes human ASPA cDNA, (hASPA) followed by green fluorescent protein (GFP) after an intraribosomal entry site. We injected CD mice with rAAV-hASPA-GFP in the striatum and thalamus or injected rAAV-GFP identically into control animals. Three to five months after the injection, we determined the presence of ASPA in the CD mouse brain by ASPA activity assay, GFP expression, and Western blot analysis. While rAAV-GFP-injected animals displayed undetectable levels of ASPA, all detection methods revealed significant ASPA levels in rAAV-hASPA-GFP-injected CD mice. We evaluated the functional effects of rAAV-hASPA-GFP-mediated ASPA expression by standard histological methods, magnetic resonance spectroscopy (MRS) for in vivo NAA levels, and magnetic resonance imaging of CD mice. rAAV-hASPA-injected animals displayed a remarkable lack of spongiform degeneration in the thalamus. However, pathology in sites unrelated to the injected areas showed no improvement in histopathology. The improvement in thalamic neuropathology was also detectable via in vivo MRI. MRS revealed that in vivo NAA levels were also reduced. These data indicate that rAAV-mediated ASPA delivery may be an interesting avenue for the treatment of CD.

KW - AAV-GFP

KW - Aspartoacylase

KW - Canavan

KW - Canavan mice

KW - Gene transfer

KW - rAAV-hASPA

UR - http://www.scopus.com/inward/record.url?scp=0038529698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038529698&partnerID=8YFLogxK

U2 - 10.1016/S1525-0016(03)00066-2

DO - 10.1016/S1525-0016(03)00066-2

M3 - Article

VL - 7

SP - 580

EP - 587

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5 I

ER -